Tony Fiorino has been named to the joint positions of chief medical officer and chief operating officer of New York-based Immune Pharmaceuticals (NASDAQ: [[ticker:IMNP]]). Fiorino will oversee research and development, clinical development, and manufacturing of Immune’s drug candidates. The company’s lead drug, bertilimumab is in mid-stage clinical testing for bullous pemphigoid, a rare autoimmune skin condition, as well as ulcerative colitis. Fiorino comes to Immune from Triumvira Immunologics of Hackensack, NJ, where he was president and CEO. His experience also includes executive roles at BrainStorm Cell Therapeutics (NASDAQ: [[ticker:BCLI]]) and EnzymeRx.
